论文部分内容阅读
目的探讨分析曲美他嗪治疗老年缺血性心肌病患者的临床疗效、心功能改善以及不良反应等情况。方法选取从2011年1月至2013年1月在本院进行治疗的68例老年缺血性心肌病的患者作为研究对象,为观察组;随机选择同时期的68例老年缺血性心肌病患者作为对照组。对照组进行一般综合治疗,观察组在对照组基础上加用曲美他嗪进行治疗。治疗3个月后,观察两组患者的临床总有效率、心功能改善以及不良反应等情况。结果治疗后观察组和对照组的总有效率分别为88.24%和57.35%,经χ2检验比较其差异均有统计学意义(P<0.05)。观察组心功能的改善情况明显优于对照组,经χ2检验比较两组差异具有统计学意义(P<0.05)。两组均未见明显不良反应。结论曲美他嗪治疗老年缺血性心肌病患者的临床疗效显著,心功能改善明显,未见明显不良反应,安全有效,值得临床推广应用。
Objective To investigate the clinical efficacy, cardiac function and adverse reactions of trimetazidine in elderly patients with ischemic cardiomyopathy. Methods Sixty-eight elderly patients with ischemic cardiomyopathy treated in our hospital from January 2011 to January 2013 were selected as the observation group and randomly selected 68 patients with elderly ischemic cardiomyopathy As a control group. Control group for general treatment, the observation group in the control group plus trimetazidine for treatment. After 3 months of treatment, the clinical total effective rate, cardiac function improvement and adverse reactions of the two groups were observed. Results After treatment, the total effective rates of the observation group and the control group were 88.24% and 57.35%, respectively. There was significant difference (P <0.05) byχ2 test. The improvement of cardiac function in the observation group was significantly better than that in the control group. There was significant difference between the two groups by χ2 test (P <0.05). No obvious adverse reactions were found in both groups. Conclusion Trimetazidine treatment of elderly patients with ischemic cardiomyopathy significant clinical effect, significant improvement of cardiac function, no obvious adverse reactions, safe and effective, worthy of clinical application.